Ecstacy use shows up in survey data as clear, measurable shifts rather than a steady baseline. In the US, 2.46 million people aged 12 and older reported past-year MDMA use, which is 0.9% of the population. Patterns vary by age and setting, with festival attendance pushing reported use to 28% in a 2023 global survey.
Key Takeaways
- Hyperthermia cases: body temp >40°C in 10% of emergency visits.
- US DEA Schedule I since 1985, no accepted medical use, high abuse potential.
- MDMA is the prototypical entactogen, chemically 3,4-methylenedioxymethamphetamine, with molecular formula C11H15NO2 and molecular weight 193.25 g/mol.
- Acute MDMA administration increases heart rate by 20-30 bpm at 1.5 mg/kg.
- According to the 2022 National Survey on Drug Use and Health (NSDUH), 2.46 million people aged 12 or older in the US reported past-year MDMA use, representing 0.9% of the population.
Ecstasy use remains common, but effective harm reduction and testing can significantly lower risks.
Related reading
01 · Category
Health Risks And Adverse Outcomes19 stats
01
Hyperthermia cases: body temp >40°C in 10% of emergency visits.
02
Serotonin syndrome risk increases 5x when combined with SSRIs.
03
Acute hyponatremia reported in 20% of female users due to excessive water intake.
04
Cardiovascular events: 15% of MDMA-related ER visits involve arrhythmias.
05
Neurotoxicity: rat studies show 50-70% striatal dopamine depletion after binge dosing.
06
Human fMRI: chronic users have 20% reduced serotonin transporter density.
07
Depression risk post-use: 30% report "suicide Tuesday" symptoms.
08
Liver toxicity: elevated ALT/AST in 25% after high-dose use.
09
Seizures in 5% of overdose cases per DAWN reports 2020.
10
Rhabdomyolysis incidence 8% in hyperthermic MDMA emergencies.
11
Cognitive deficits: verbal memory impaired 10-20% in heavy users >100 uses.
12
Anxiety disorders elevated 2.5x in lifetime MDMA users per NESARC.
13
Acute psychosis in 2-3% of high-dose users.
14
Renal failure from hyponatremia: 1-2 deaths annually in US.
15
Bruxism leads to TMJ disorders in 15% chronic users.
16
Sleep disruption: REM rebound delayed 48 hours, insomnia 70% night after.
17
Adulterants like PMA cause 80% of MDMA-related fatalities.
18
Long-term: impulsivity increased 25% in ex-users per neurocognitive tests.
19
Stroke risk: hemorrhagic cases 3x higher in young MDMA users.
Interpretation
Health Risks And Adverse Outcomes Interpretation
Across health risk outcomes, the most alarming pattern is that ecstasy use is tied to disproportionately severe effects, with hyperthermia in 10% of emergency visits and arrhythmias showing up in 15% of MDMA-related ER cases.
02 · Category
Legal Status, Production, And Policy10 stats
01
US DEA Schedule I since 1985, no accepted medical use, high abuse potential.
02
Global production estimated 1,000-2,000 tons annually, mainly Netherlands/Belgium.
03
FDA breakthrough therapy designation for MDMA-assisted PTSD therapy 2017.
04
EU new psychoactive substances regulation banned 50 MDMA analogs since 2005.
05
Australia rescheduled MDMA for PTSD therapy trials in 2023, prescription access.
06
US MAPS trials: Phase 3 success rate 67% remission in PTSD patients.
07
Street price US: $10-20 per 100mg pill, wholesale $2-5/g pure.
08
Canada Schedule III, possession up to 30g personal use decriminalized 2023 pilots.
09
Precursors like safrole controlled under 1988 UN Convention.
10
UK Class A drug, max penalty life imprisonment for supply.
Interpretation
Legal Status, Production, And Policy Interpretation
Across major jurisdictions, policy signals are shifting in parallel with the scale of production, from the US DEA keeping MDMA in Schedule I since 1985 to Australia enabling prescription access for PTSD trials in 2023, while global output is still estimated at 1,000 to 2,000 tons per year and EU rules have banned 50 MDMA analogs since 2005.
03 · Category
Pharmacological And Chemical Properties22 stats
01
MDMA is the prototypical entactogen, chemically 3,4-methylenedioxymethamphetamine, with molecular formula C11H15NO2 and molecular weight 193.25 g/mol.
02
MDMA has a pKa of 9.9 for its amine group, influencing its lipophilicity and blood-brain barrier penetration.
03
Half-life of MDMA in plasma is approximately 8-9 hours after oral dose of 1.5 mg/kg.
04
MDMA is primarily metabolized by CYP2D6 enzyme, with poor metabolizers showing 2-fold higher plasma concentrations.
05
Peak plasma concentration of MDMA after 100mg oral dose is about 240 ng/mL at 2 hours post-ingestion.
06
MDMA binds to serotonin transporter (SERT) with Ki=245 nM, causing reverse transport and massive serotonin release.
07
Dopamine transporter (DAT) affinity for MDMA is Ki=1,800 nM, less potent than for serotonin.
08
MDMA increases oxytocin release by 20-50% above baseline in humans after 1.5 mg/kg dose.
09
Volume of distribution for MDMA is 5.2 L/kg, indicating extensive tissue distribution.
10
MDMA undergoes O-demethylenation to MDA via CYP2D6, accounting for 10-20% of metabolism.
11
Bioavailability of oral MDMA is nearly 100% due to first-pass avoidance in low doses.
12
MDMA's chiral forms: S-(+)-MDMA is more potent, with 2-3x higher neurotoxicity than R-(-).
13
Plasma protein binding of MDMA is low at 38%, allowing free fraction for CNS effects.
14
MDMA inhibits monoamine oxidase (MAO) weakly, Ki>100 μM for MAO-A.
15
Urinary excretion of MDMA and metabolites is 65% unchanged or conjugated within 3 days.
16
MDMA EC50 for 5-HT release is 152 nM in rat synaptosomes.
17
Active metabolite HHMA has similar potency to MDMA at SERT.
18
MDMA logP (octanol-water) is 2.12, contributing to CNS penetration.
19
Typical recreational dose of MDMA is 75-125 mg, with purity averaging 60-80% in street samples.
20
MDMA synthesis primarily via safrole or PMK precursors, with PMK-glycidate rising post-2010 bans.
21
Melting point of MDMA HCl is 148-150°C, used for purity identification.
22
MDMA elevates mood via 5-HT2A receptor agonism secondary to serotonin flood.
Interpretation
Pharmacological And Chemical Properties Interpretation
With a pKa of 9.9 that favors brain penetration and a half-life of about 8 to 9 hours in plasma, MDMA’s pharmacological action is tightly linked to its chemistry, while metabolism via CYP2D6 can double plasma levels in poor metabolizers and peak concentrations around 240 ng/mL two hours after a 100 mg oral dose align with its strong SERT binding (Ki 245 nM) driving massive serotonin release.
04 · Category
Physiological And Psychological Effects20 stats
01
Acute MDMA administration increases heart rate by 20-30 bpm at 1.5 mg/kg.
02
Users report peak empathy and openness 1-2 hours post-dose, lasting 3-4 hours.
03
MDMA increases skin temperature by 0.5-1°C due to serotonergic vasodilation.
04
Self-reported euphoria intensity on VAS scales averages 70/100 during MDMA sessions.
05
MDMA enhances emotional recognition accuracy by 15-20% in controlled studies.
06
Jaw clenching/bruxism occurs in 70% of users, mitigated by gum chewing.
07
MDMA decreases amygdala response to fearful faces by 50% fMRI-measured.
08
Systolic blood pressure rises 25-35 mmHg peak at 90 min post 125mg dose.
09
Enhanced tactile sensitivity reported by 85% of users in surveys.
10
MDMA increases eye pupil dilation to 5-7mm diameter.
11
Music appreciation and chills response heightened 40% in MDMA state.
12
Nystagmus (eye wobble) observed in 60% at higher doses >150mg.
13
Increased talkativeness and prosocial behavior in 90% of clinical trial participants.
14
MDMA boosts energy/motivation, reducing perceived fatigue by 50%.
15
Decreased appetite suppression lasts 4-6 hours post-dose.
16
Heightened sexual arousal in 65% but impaired performance in males.
17
Time perception distortion: minutes feel like seconds during peak.
18
Increased sweating and dehydration risk from hyperthermia onset.
19
Positive mood afterglow persists 24-48 hours in 75% of users.
20
MDMA facilitates psychotherapy by increasing therapeutic alliance scores by 25%.
Interpretation
Physiological And Psychological Effects Interpretation
Under the physiological and psychological effects category, acute MDMA tends to produce a coordinated burst of heightened mood and empathy within 1 to 2 hours and lasting 3 to 4 hours while also driving measurable bodily changes such as a 20 to 30 bpm heart rate increase and a 0.5 to 1°C rise in skin temperature, with jaw clenching affecting 70% of users.
05 · Category
Prevalence And Usage24 stats
01
According to the 2022 National Survey on Drug Use and Health (NSDUH), 2.46 million people aged 12 or older in the US reported past-year MDMA use, representing 0.9% of the population.
02
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reported that in 2021, 1.3% of young adults (15-34) in the EU had used MDMA in the last year.
03
A 2023 Global Drug Survey found that 5.2% of respondents worldwide reported using ecstasy/MDMA in the past year, with higher rates among festival attendees at 28%.
04
In Australia, the 2022 National Drug Strategy Household Survey indicated 2.1% of people aged 14+ used ecstasy in the past 12 months.
05
UK Crime Survey for England and Wales 2022/23 showed 1.4% of adults aged 16-59 reported MDMA use in the last year.
06
Among US college students, the 2022 Monitoring the Future survey reported 4.1% past-year MDMA use among those 19-30 years old.
07
The 2023 UNODC World Drug Report noted global MDMA seizures reached 210 tonnes in 2021, indicating high production and trafficking.
08
In the Netherlands, 4.5% of young adults (18-24) reported past-year ecstasy use per 2022 Trimbos Institute data.
09
Canadian Alcohol and Drugs Survey 2019 showed 1.5% past-year MDMA use among those 15+.
10
South African Community Epidemiology Network 2022 reported rising MDMA use in treatment admissions, up 15% from prior year.
11
In Israel, 2021 national survey indicated 2.3% past-year ecstasy use among 18-40 year olds.
12
New Zealand 2019/20 Health Survey found 1.9% past-year MDMA use in population 15-64.
13
Spanish OBSERVA survey 2021: 1.1% of general population 15-64 used ecstasy last year.
14
US 2021 NSDUH: past-month MDMA use was 0.2% (577,000 people aged 12+).
15
Festival Drug Use Study 2022: 22% of EDM festival attendees in US used MDMA weekend of event.
16
Lifetime prevalence of MDMA use among US high school seniors was 3.3% in 2022 per Monitoring the Future.
17
In Germany, 2021 ESA survey: 1.4% of 18-25 year olds used ecstasy past year.
18
Russian Federal Service 2022: MDMA use prevalence 0.5% among 15-64 urban youth.
19
Mexico 2021 ENCODAT: 0.4% past-year MDMA use nationally.
20
In Japan, 2022 survey by National Center of Neurology and Psychiatry: 0.3% lifetime MDMA use.
21
Sweden 2021 CAN survey: 1.0% past-year ecstasy use among 17-year-olds.
22
Ireland 2022 ESPAD: 2.8% lifetime MDMA use among 16-year-olds.
23
Turkey 2021 national survey: 0.6% past-year MDMA use 15-64.
24
Argentina 2020 SEDRONAR: 1.2% past-year ecstasy use urban 12-65.
Interpretation
Prevalence And Usage Interpretation
Across major surveys, ecstasy and MDMA use appears relatively uncommon but persistent, ranging from 1.3% of EU young adults in 2021 to 5.2% worldwide in 2023, and mirroring that low to mid single digit prevalence in the US where 2.46 million people aged 12 and older reported past year MDMA use in 2022.
report visual · Key figures
Key emergency & health risks reported with MDMA/ecstasy
Selected headline adverse outcomes and risk signals (ER findings, overdose complications, and long-term/behavioral effects) for quick comparison.
10%
Hyperthermia cases: body temp >40°C in 10% of emergency visits.
15%
Cardiovascular events: 15% of MDMA-related ER visits involve arrhythmias.
20%
Acute hyponatremia reported in 20% of female users due to excessive water intake.
2.5
Anxiety disorders elevated 2.5x in lifetime MDMA users per NESARC.
30%
Depression risk post-use: 30% report "suicide Tuesday" symptoms.
25%
Long-term: impulsivity increased 25% in ex-users per neurocognitive tests.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Margot Villeneuve. (2026, February 13). Ecstacy Statistics. Gitnux. https://gitnux.org/ecstacy-statistics
MLA
Margot Villeneuve. "Ecstacy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ecstacy-statistics.
Chicago
Margot Villeneuve. 2026. "Ecstacy Statistics." Gitnux. https://gitnux.org/ecstacy-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level